Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atenolol + doxazosin
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of a beta-blocker (atenolol) and an alpha-blocker (doxazosin) used primarily for the treatment of hypertension. Atenolol selectively blocks beta-1 adrenergic receptors in the heart, reducing heart rate and contractility, while doxazosin blocks alpha-1 adrenergic receptors, causing vasodilation and reducing peripheral vascular resistance. This dual mechanism provides enhanced blood pressure control, particularly in patients whose hypertension is inadequately controlled with either agent alone.
02
Targets
ADRB1 (β1)ADRA1A (α1A)
Beyond the preview
Go deeper on atenolol + doxazosin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atenolol + doxazosin.